Hematologists & Oncologists from Across Country Met to Discuss Latest Updates in Care On August 4-5, 2023, the Binaytara Foundation held
Dr. Talha Badar of Mayo Clinic discusses the results of Quantum First, a randomized, phase III trial evaluating the efficacy of Quizartinib
On July 31, 2023, the U.S. Food and Drug Administration approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) for primary advanced or recurrent endometrial cancer (EC)
On August 2, 2023, the U.S. Food and Drug Administration approved trifluridine and tipiracil (LONSURF) with bevacizumab for the treatment of metastatic
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher
On June 20, 2023, the U.S. Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) in combination with enzalutamide for patients with
On July 20, 2023, the U.S. Food and Drug Administration (FDA) approved quizartinib (Vanflyta) for adult patients newly diagnosed with acute myeloid
On June 15, 2023, the U.S. Food and Drug Administration approved Glofitamab-gxbm (Columvi) for the treatment of adult patients with relapsed or
X-7/7 trial: Alternative fixed dosing of capecitabine associated with similar efficacy with better safety profile By Drs. Arya Mariam Roy &
By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant, EGFR-Mutated Metastatic